Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLH12016 Plus Novel Hormonal Agent in Advanced Prostate Cancer
NCT07104110Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
01
Overview
A Phase 2 trial of QLH12016 in Metastatic Prostate Cancer (mPC), sponsored by Qilu Pharmaceutical. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
QLH12016
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT07104110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104110.